文献类型：期刊文献

英文题名：Magnetic-Based Microfluidic Device for On-Chip Isolation and Detection of Tumor-Derived Exosomes

作者：Xu, Huiying[1];Liao, Chong[1];Zuo, Peng[1];Liu, Ziwen[2];Ye, Bang-Ce[1]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Lab Biosyst & Microanal, Shanghai 200237, Peoples R China;[2]First Peoples Hosp Shangqiu City, Dept Nucl Med, Shangqiu 476000, Peoples R China

年份：2018

卷号：90

期号：22

起止页码：13451

外文期刊名：ANALYTICAL CHEMISTRY

收录：;EI(收录号：20184205948676);WOS:【SCI-EXPANDED(收录号:WOS:000451246100044)】；

基金：This work was supported by the National Natural Science Foundation of China (Grants 21335003, 21575089, and 21705047), the Fundamental Research Funds for the Central Universities (Grant 222201814030), and the Chinese Post Doctoral Fund (Grant 2017M621380).

语种：英文

外文关键词：Diagnosis - Signal transduction - Phospholipids - Body fluids - Noninvasive medical procedures - Silicones - Microfluidics

摘要：Exosomes are membrane-enclosed phospholipid extracellular vesicles, which can act as mediators of intercellular communication. Although the original features endow tumor-derived exosomes great potential as biomarkers, efficient isolation and detection methods remain challenging. Here, we presented a two-stage microfluidic platform (ExoPCD-chip), which integrates on-chip isolation and in situ electrochemical analysis of exosomes from serum. To promote exosomes capture efficiency, an improved staggered Y-shaped micropillars mixing pattern was designed to create anisotropic flow without any surface modification. By combining magnetic enrichment based on specific phosphatidylserine-Tim4 protein recognition with a new signal transduction strategy in a chip for the first time, the proposed platform enables highly sensitive detection for CD63 positive exosomes as low as 4.39 X 10(3) particles/mL with a linear range spanning 5 orders of magnitude, which is substantially better than the existing methods. The reduced volume of sample (30 mu L) and simple affinity method also make it ideal for rapid downstream analysis of complex biofluids within 3.5 h. As a proof-of-concept, we performed exosomes analysis in human serum and liver cancer patients can be well discriminated from the healthy controls by the ExoPCD-chip. These results demonstrate that this proposed ExoPCD-chip may serve as a comprehensive exosome analysis tool and potential noninvasive diagnostic platform.